How Many Verastem Inc (NASDAQ:VSTM)’s Analysts Are Bullish?

October 13, 2017 - By Darrin Black

 How Many Verastem Inc (NASDAQ:VSTM)'s Analysts Are Bullish?
Investors sentiment increased to 1.17 in Q2 2017. Its up 0.07, from 1.1 in 2017Q1. It increased, as 5 investors sold Verastem Inc shares while 18 reduced holdings. 13 funds opened positions while 14 raised stakes. 8.68 million shares or 12.61% more from 7.71 million shares in 2017Q1 were reported.
Deer Vii And invested in 1.19M shares. 299,125 are owned by Connor Clark Lunn Invest Mgmt Limited. Raymond James Finance Serv reported 0% stake. Moreover, First Republic Management has 0% invested in Verastem Inc (NASDAQ:VSTM) for 17,500 shares. Renaissance Technology Lc has invested 0.01% in Verastem Inc (NASDAQ:VSTM). Grt Prtnrs Ltd Liability Corp owns 22,405 shares for 0.03% of their portfolio. Highbridge Mngmt Ltd Liability Corporation holds 100,000 shares or 0% of its portfolio. Art Advsr holds 99,594 shares. Florida-based Raymond James has invested 0% in Verastem Inc (NASDAQ:VSTM). Artal Gru Sa owns 0.02% invested in Verastem Inc (NASDAQ:VSTM) for 500,000 shares. Howland Cap Mngmt has 294,007 shares. Hightower Advsr Ltd Limited Liability Company holds 0% in Verastem Inc (NASDAQ:VSTM) or 10,014 shares. Prelude Cap Mngmt Limited Co holds 3,000 shares or 0% of its portfolio. Parsons Inc Ri holds 0% of its portfolio in Verastem Inc (NASDAQ:VSTM) for 14,500 shares. Natl Bank Of America De stated it has 0% in Verastem Inc (NASDAQ:VSTM).

Since May 15, 2017, it had 1 insider purchase, and 0 sales for $73,500 activity.

Verastem Inc (NASDAQ:VSTM) Ratings Coverage

Among 10 analysts covering Verastem (NASDAQ:VSTM), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Verastem had 26 analyst reports since September 9, 2015 according to SRatingsIntel. On Thursday, September 17 the stock rating was maintained by H.C. Wainwright with “Buy”. The company was downgraded on Monday, September 28 by Roth Capital. UBS downgraded the shares of VSTM in report on Tuesday, September 29 to “Neutral” rating. Oppenheimer maintained the stock with “Buy” rating in Wednesday, August 16 report. TH Capital downgraded the stock to “Neutral” rating in Monday, September 28 report. The stock of Verastem Inc (NASDAQ:VSTM) earned “Overweight” rating by Cantor Fitzgerald on Wednesday, September 6. Oppenheimer maintained the shares of VSTM in report on Tuesday, July 25 with “Buy” rating. The stock of Verastem Inc (NASDAQ:VSTM) has “Hold” rating given on Tuesday, August 9 by Jefferies. Oppenheimer maintained Verastem Inc (NASDAQ:VSTM) rating on Tuesday, August 8. Oppenheimer has “Buy” rating and $600 target. The firm earned “Outperform” rating on Tuesday, September 29 by Raymond James. Below is a list of Verastem Inc (NASDAQ:VSTM) latest ratings and price target changes.

25/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $17.0 Maintain
06/09/2017 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Overweight Upgrade
16/08/2017 Broker: Oppenheimer Rating: Buy Maintain
10/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.5000
08/08/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain
25/07/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain
12/07/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain
26/06/2017 Broker: Jefferies Rating: Hold New Target: $1.5000 Maintain
26/06/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain
16/06/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain

The stock decreased 3.97% or $0.18 on October 13, reaching $4.35. About 717,648 shares traded. Verastem Inc (NASDAQ:VSTM) has risen 71.53% since October 13, 2016 and is uptrending. It has outperformed by 54.83% the S&P500.

Verastem, Inc. is a biopharmaceutical company. The company has market cap of $160.92 million. The Firm is focused on discovering and developing drugs to improve outcomes for patients with cancer. It currently has negative earnings. The Firm operates in the segment of developing drugs for the treatment of cancer.

Another recent and important Verastem Inc (NASDAQ:VSTM) news was published by Businesswire.com which published an article titled: “Verastem Appoints NgocDiep Le, MD, PhD as Chief Medical Officer” on October 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.